Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SG Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Fat Taste Sensory Study

NCT03540693
View directory record Official record
Conditions
Bariatric Surgery Candidate, Bariatric Surgical Procedure
Interventions
RYGB, SG, LAGB
Procedure
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 64 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 30, 2026, 7:48 PM EDT
Active, not recruiting Phase 4 Interventional

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

NCT06803888
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions
Interventions
Bariatric Surgery, Semaglutide, Tirzepatide
Procedure · Drug
Lead sponsor
Ali Aminian
Other
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 7:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

NCT01631552
View directory record Official record
Conditions
Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer
Interventions
Sacituzumab Govitecan-hziy (SG)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
12
States / cities
Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 30, 2026, 7:48 PM EDT
Completed Not applicable Interventional

Phantom Motor Execution Via MPR, VR/AR, and SG, as a Treatment of PLP

NCT03112928
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Phantom Motor Execution, Phantom Motor Imagery
Device
Lead sponsor
Integrum
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 7:48 PM EDT
Completed Not applicable Interventional

Strategy Based Technique to Enhance Memory (STEM) for Improving New Learning and Memory (NLM) in Moderate to Severe TBI

NCT04054596
View directory record Official record
Conditions
Traumatic Brain Injury, Cognitive Impairment
Interventions
SME
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 30, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

A Study of Sacituzumab Govitecan in People With Mesothelioma

NCT06477419
View directory record Official record
Conditions
Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura
Interventions
Sacituzumab govitecan-hziy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

NCT07504588
View directory record Official record
Conditions
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
19
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 7:48 PM EDT
Terminated Not applicable Interventional

Compassion Meditation and ReliefLink App for Suicidal, Low-Income, African Americans

NCT03463980
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Compassion meditation (CM), Support group (SG)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 64 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 30, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

NCT06263543
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
Interventions
Sacituzumab govitecan
Drug
Lead sponsor
Reshma L. Mahtani, D.O.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 7:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Change in Reward System Activation and Gut Microbiota Following RYGB and Sleeve Gastrectomy for Weight Loss vs. Control-Heads Up Ancillary

NCT02735564
View directory record Official record
Conditions
Bariatric Surgery Candidate
Interventions
Bariatric Surgery
Procedure
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
21 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 30, 2026, 7:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

NCT03964727
View directory record Official record
Conditions
Metastatic Solid Tumor
Interventions
Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
31
States / cities
Anchorage, Alaska • Glendale, Arizona • Goodyear, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 7:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Insulin Sensitivity After Weight Loss

NCT00627484
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Gastric bypass, Gastric banding, Sleeve gastrectomy, Very low calorie diet
Procedure · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 30, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT07339059
View directory record Official record
Conditions
Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
Sacituzumab govitecan, Atezolizumab, Durvalumab
Drug
Lead sponsor
Bindu R Potugari
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 7:48 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

NCT04863885
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma
Interventions
Ipilimumab, Nivolumab, Sacituzumab govitecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 30, 2026, 7:48 PM EDT
Completed No phase listed Observational

CryoValve® SG Aortic Human Heart Valve Combination Study

NCT01236469
View directory record Official record
Conditions
Aortic Valve Stenosis, Aortic Valve Insufficiency
Interventions
Echocardiogram
Procedure
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
6 Years to 27 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 30, 2026, 7:48 PM EDT
Completed No phase listed Observational Results available

CryoValve SG Pulmonary Human Heart Valve Post Clearance Study

NCT01092442
View directory record Official record
Conditions
Pulmonary Valve Stenosis, Pulmonary Valve Insufficiency, Aortic Valve Stenosis, Aortic Valve Insufficiency
Interventions
Echocardiogram
Procedure
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
Not listed
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 30, 2026, 7:48 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sacituzumab Govitecan-hziy (SG), Docetaxel
Biological · Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
37
States / cities
Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 30, 2026, 7:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mail Outreach To Increase Vaccination Acceptance Through Engagement

NCT02243774
View directory record Official record
Conditions
Influenza, Human, Influenza, Human Flu
Interventions
Core letter signed by Surgeon General, Core letter signed by the Director of the National Vaccine Program, Core letter signed by Surgeon General + implementation prompt, Core letter signed by SG + enhanced implementation prompt
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
66 Years and older
Enrollment
228,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 30, 2026, 7:48 PM EDT
Completed Not applicable Interventional Results available

Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes

NCT00432809
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Gastric bypass, Sleeve Gastrectomy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
20 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 30, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

NCT07063212
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Sacituzumab Govitecan, Cetuximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 30, 2026, 7:48 PM EDT
Completed Phase 3 Interventional Results available

Tinnitus Retraining Therapy Trial

NCT01177137
View directory record Official record
Conditions
Subjective Tinnitus
Interventions
Conventional sound generator (SG), Placebo sound generator (placebo SG), Standard of Care (SC), Directive Counseling (DC)
Device · Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
Camp Pendleton, California • San Diego, California • Travis Air Force Base, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 30, 2026, 7:48 PM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes

NCT01586065
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 30, 2026, 7:48 PM EDT
Recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 7:48 PM EDT
Completed Phase 4 Interventional Results available

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

NCT04319198
View directory record Official record
Conditions
Metastatic Solid Tumors
Interventions
Sacituzumab Govitecan-hiy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
San Francisco, California • Aurora, Colorado • Newark, Delaware + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 30, 2026, 7:48 PM EDT